Registered title, quoted from ClinicalTrials.gov
Perioperative Tislelizumab for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung Cancer
An open trial on lung cancer, registered on ClinicalTrials.gov. Led by Shanghai Chest Hospital; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT06659042, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 7
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (7 points)Hide the checklist
18 years to Not stated; sex: all
Registered eligibility fields
Histologically or cytologically confirmed stage II-IIIB (N2) non-squamous non-small cell lung cancer (NSCLC) (AJCC 8th edition).
Inclusion criterion 3
Used any herbal medicine to control cancer within 14 days prior to the first dose of the study drug.
Exclusion criterion 4
ECOG performance status score ≤ 1.
Inclusion criterion 8
At least one measurable lesion as defined by RECIST v1.1.
Inclusion criterion 6
Known history of human immunodeficiency virus (HIV) infection.
Exclusion criterion 11
Patients of childbearing potential must be willing to use effective contraception during the study and for 120 days after the last dose of tislelizumab.
Inclusion criterion 11
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06659042, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Able to provide written informed consent (ICF) and able to understand and comply with the study requirements and assessment schedule.
- Male or female aged ≥18 years at the time of signing the ICF.
- Histologically or cytologically confirmed stage II-IIIB (N2) non-squamous non-small cell lung cancer (NSCLC) (AJCC 8th edition).
- With Known KRAS gene mutation.
- Evaluated by medical and surgical discussion to be eligible for R0 resection with curative intent prior to study enrollment.
- At least one measurable lesion as defined by RECIST v1.1.
- Eligible to receive platinum-based doublet chemotherapy.
- ECOG performance status score ≤ 1.
- Adequate organ function during the screening period
- Good cardiopulmonary function, meeting the requirements for surgical resection with curative intent.
- Patients of childbearing potential must be willing to use effective contraception during the study and for 120 days after the last dose of tislelizumab.
Exclusion Criteria:
Patients meeting any of the following criteria are not eligible for enrollment:
- Previously received any treatment for the current lung cancer, including radiotherapy and all systemic anti-tumor treatments, including chemotherapy, immunotherapy, targeted therapy, or anti-angiogenic therapy.
- Presence of locally advanced, unresectable disease, regardless of disease stage or presence of metastases.
- Received other approved systemic immunomodulatory agents (including but not limited to interferon, interleukin-2, tumor necrosis factor, thymosin α1, and thymalfasin) within 4 weeks prior to the first dose.
- Used any herbal medicine to control cancer within 14 days prior to the first dose of the study drug.
- Received live or attenuated live vaccines within 4 weeks prior to enrollment or expected to require live or attenuated live vaccines during the study or within 5 months after the last dose of tislelizumab.
- Any condition requiring systemic corticosteroid therapy (prednisone or equivalent >10 mg/day) or other immunosuppressive therapy within 14 days prior to the first dose of the study drug, which the investigator believes may affect the study treatment.
- Active autoimmune disease requiring systemic treatment, which the investigator believes may affect the study treatment.
- Interstitial lung disease, non-infectious pneumonitis, or uncontrolled other diseases, including diabetes, pulmonary fibrosis, acute lung disease, etc., which the investigator believes may affect the study treatment.
- History of major diseases or clinical manifestations that may affect organ system function, which the investigator believes may affect the study treatment.
- Severe chronic or active infections requiring systemic antibacterial, antifungal, or antiviral treatment within 14 days prior to the first dose of the study drug (including tuberculosis infection, etc.).
- Known history of human immunodeficiency virus (HIV) infection.
- Previously undergone allogeneic stem cell transplantation or organ transplantation.
Quoted from ClinicalTrials.gov, NCT06659042, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT06659042, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.